John B. Bode Buys 10,000 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $318,400. This represents a 33.33 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $8.01 on Friday. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $433.47 million, a P/E ratio of -4.07 and a beta of 1.98. The stock’s fifty day moving average is $7.90 and its two-hundred day moving average is $8.18.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. Equities analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics in the fourth quarter valued at $53,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at $94,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at $94,000. Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at $95,000. Finally, Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at $127,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analyst Weigh In

ZVRA has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group lifted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Finally, Guggenheim lifted their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $22.29.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.